TY  - GEN
AU  - Perez,E A
AU  - Hillman,D W
AU  - Dentchev,T
AU  - Le-Lindqwister,N A
AU  - Geeraerts,L H
AU  - Fitch,T R
AU  - Liu,H
AU  - Graham,D L
AU  - Kahanic,S P
AU  - Gross,H M
AU  - Patel,T A
AU  - Palmieri,F M
AU  - Dueck,A C
TI  - North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
SN  - 1569-8041
PY  - 2010///0506
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bevacizumab
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Capecitabine
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Metastasis
KW  - Taxoids
KW  - Treatment Outcome
KW  - United States
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdp512
ER  -